These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
281 related articles for article (PubMed ID: 32590815)
1. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison. Ismail G; Obrişcă B; Jurubiţă R; Andronesi A; Sorohan B; Vornicu A; Sinescu I; Hârza M Medicine (Baltimore); 2020 Jun; 99(26):e21000. PubMed ID: 32590815 [TBL] [Abstract][Full Text] [Related]
2. An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression. Obrișcă B; Vornicu A; Mocanu V; Dimofte G; Andronesi A; Bobeică R; Jurubiță R; Sorohan B; Caceaune N; Ismail G Sci Rep; 2023 Nov; 13(1):20119. PubMed ID: 37978255 [TBL] [Abstract][Full Text] [Related]
3. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Smerud HK; Bárány P; Lindström K; Fernström A; Sandell A; Påhlsson P; Fellström B Nephrol Dial Transplant; 2011 Oct; 26(10):3237-42. PubMed ID: 21378156 [TBL] [Abstract][Full Text] [Related]
4. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)]. Nagy J; Sági B; Máté J; Vas T; Kovács T Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436 [TBL] [Abstract][Full Text] [Related]
5. Corticosteroid therapy in IgA nephropathy with minimal proteinuria and high renal pathological score: A single‑center cohort study. Tang Y; He H; Sun W; Hu P; Chen X; Xu X Mol Med Rep; 2018 Oct; 18(4):4103-4112. PubMed ID: 30132546 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of corticosteroid therapy for IgA nephropathy patients stratified by kidney function and proteinuria. Nagasawa Y; Yamamoto R; Shinzawa M; Shoji T; Hasuike Y; Nagatoya K; Yamauchi A; Hayashi T; Kuragano T; Moriyama T; Isaka Y Clin Exp Nephrol; 2020 Oct; 24(10):927-934. PubMed ID: 32642919 [TBL] [Abstract][Full Text] [Related]
7. Combination therapy of low-dose cyclosporine and steroid in adults with IgA nephropathy . Ihm HS; Lee JY; Hwang HS; Kim YG; Moon JY; Lee SH; Jeong KH; Lee TW; Ihm CG Clin Nephrol; 2019 Sep; 92(3):131-140. PubMed ID: 31232271 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study. Yang YZ; Chen P; Liu LJ; Cai QQ; Shi SF; Chen YQ; Lv JC; Zhang H BMC Nephrol; 2019 Aug; 20(1):297. PubMed ID: 31382914 [TBL] [Abstract][Full Text] [Related]
9. Insights on Nefecon Barratt J; Kristensen J; Pedersen C; Jerling M Drug Des Devel Ther; 2024; 18():3415-3428. PubMed ID: 39100224 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lafayette R; Kristensen J; Stone A; Floege J; Tesař V; Trimarchi H; Zhang H; Eren N; Paliege A; Reich HN; Rovin BH; Barratt J; Lancet; 2023 Sep; 402(10405):859-870. PubMed ID: 37591292 [TBL] [Abstract][Full Text] [Related]
11. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study. Tesar V; Troyanov S; Bellur S; Verhave JC; Cook HT; Feehally J; Roberts IS; Cattran D; Coppo R; J Am Soc Nephrol; 2015 Sep; 26(9):2248-58. PubMed ID: 25677392 [TBL] [Abstract][Full Text] [Related]
12. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review. Liao J; Zhou Y; Xu X; Huang K; Chen P; Wu Y; Jin B; Hu Q; Chen G; Zhao S Front Immunol; 2022; 13():926517. PubMed ID: 36685528 [TBL] [Abstract][Full Text] [Related]
13. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Fellström BC; Barratt J; Cook H; Coppo R; Feehally J; de Fijter JW; Floege J; Hetzel G; Jardine AG; Locatelli F; Maes BD; Mercer A; Ortiz F; Praga M; Sørensen SS; Tesar V; Del Vecchio L; Lancet; 2017 May; 389(10084):2117-2127. PubMed ID: 28363480 [TBL] [Abstract][Full Text] [Related]
14. Changes in Proteinuria and Side Effects of Corticosteroids Alone or in Combination with Azathioprine at Different Stages of IgA Nephropathy. Sarcina C; Tinelli C; Ferrario F; Pani A; De Silvestri A; Scaini P; Del Vecchio L; Alberghini E; Buzzi L; Baragetti I; Pozzi C Clin J Am Soc Nephrol; 2016 Jun; 11(6):973-981. PubMed ID: 27129712 [TBL] [Abstract][Full Text] [Related]
15. An update on corticosteroid treatment for IgA nephropathy. Ghaddar M; Barratt J; Barbour SJ Curr Opin Nephrol Hypertens; 2023 May; 32(3):263-270. PubMed ID: 36866805 [TBL] [Abstract][Full Text] [Related]
16. Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy. Barratt J; Lafayette RA; Rovin BH; Fellström B Expert Rev Clin Immunol; 2023; 19(7):699-710. PubMed ID: 37103889 [TBL] [Abstract][Full Text] [Related]
17. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade. Chen J; Liu S; Xu H; Wang W; Xie Y; Tang W; Yuan Q; Zheng L; Lin L; Fu S; Shen J Med Sci Monit; 2020 Aug; 26():e922839. PubMed ID: 32822333 [TBL] [Abstract][Full Text] [Related]
18. Corticosteroid in IgA nephropathy with moderate proteinuria: A retrospective cohort study. Wang Y; Yu J; Jiang Y; Li J; Yimamuyushan A; Xia X; Fan L; Huang F; Chen W; Liu Q Nephrology (Carlton); 2024 May; 29(5):268-277. PubMed ID: 38186010 [TBL] [Abstract][Full Text] [Related]
19. Treatment of IgA nephropathy. Pozzi C J Nephrol; 2016 Feb; 29(1):21-5. PubMed ID: 26577268 [TBL] [Abstract][Full Text] [Related]
20. Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. Liu LJ; Yang YZ; Shi SF; Bao YF; Yang C; Zhu SN; Sui GL; Chen YQ; Lv JC; Zhang H Am J Kidney Dis; 2019 Jul; 74(1):15-22. PubMed ID: 30922594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]